---
title: "TuHURA Biosciences, Inc. (HURA.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/HURA.US.md"
symbol: "HURA.US"
name: "TuHURA Biosciences, Inc."
industry: "生物技术"
---

# TuHURA Biosciences, Inc. (HURA.US)

| Item | Detail |
|------|--------|
| Industry | 生物技术 |
| Location | 美股市场 |
| Website | [www.tuhurabio.com](https://www.tuhurabio.com) |

## Company Profile

TuHURA Biosciences, Inc.是一家临床阶段的免疫肿瘤学公司，开发用于癌症免疫治疗的新技术。该公司的主要产品候选包括 IFx2.0，这是一种内源性免疫激动剂，旨在克服对检查点抑制剂的初级耐药性。公司还准备启动一项单中心随机安慰剂对照的 III 期注册试验，研究 IFx-2.0 作为 Keytruda 的辅助治疗。此外，公司还在开发 Delta 受体技术，以开发肿瘤微环境调节剂，形式为首创的双特异性抗体 - 肽结合物和抗体 - 药物结合物，针对髓源抑制细胞。此外，公司还在开发 Immune Fx；IFx-3.0，这是一种 mRNA 内源性免疫激动剂候选，用于静脉注射或自体全细胞...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -3.46 | 318/606 | - | - | - |
| PB | 6.15 | 326/606 | 12.30 | 6.70 | 4.23 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-03T05:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 2 | 50% |
| Overweight | 1 | 25% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 3.33 |
| Highest Target | 15.00 |
| Lowest Target | 9.25 |

## References

- [Company Overview](https://longbridge.com/en/quote/HURA.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/HURA.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/HURA.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.